-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Illumina this week announced a collaboration with Boehringer Ingelheim to develop companion diagnostics (CDx) for multiple programs in Boehringer Ingelheim's oncology pipeline
.
The partnership aims to help patients with advanced cancer choose treatment options and enable precision medicine
.
The collaboration covers current and future CDx programs, and Illumina plans to develop a companion diagnostic test based on the content of the TruSight™ Oncology 500 (TSO 500)
.
In the first project, they will collaborate to develop a companion diagnostic for one of Boehringer Ingelheim's clinical trial drugs
.
The TSO 500 is a research-only pan-cancer assay that identifies 523 known and emerging tumor biomarkers
.
The TSO 500 utilizes DNA and RNA from tumor samples to identify key variants critical to cancer progression, such as small DNA variants, gene fusions and splice variants
.
Based on the content of the TSO 500, Illumina will add an in vitro diagnostic test to the TruSight Oncology product family
.
This comprehensive tumor analysis approach will utilize similar chemistry and analytical methods to the TSO 500
.
"We are delighted that Boehringer Ingelheim has selected Illumina as its long-term partner to develop companion diagnostics for cancer treatment," said Joydeep Goswami, chief strategy and corporate development officer at Illumina.
"Illumina
will continue to provide leading-edge assays in tissue biopsy and liquid biopsy.